OVID - オ―ビッド・セラピュ―ティクス (Ovid Therapeutics Inc.)

OVIDのニュース

   Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Northern Trust Corp  2021/12/03 09:22:41 Transcript Daily
Northern Trust Corp trimmed its stake in Ovid Therapeutics Inc. (NASDAQ:OVID) by 83.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 82,052 shares of the companys stock after selling 399,811 shares during the quarter. Northern Trust Corps holdings in Ovid Therapeutics were worth $321,000 as of its []
   Ovid Therapeutics Inc. (NASDAQ:OVID) Short Interest Down 39.2% in November  2021/11/30 09:40:41 Transcript Daily
Ovid Therapeutics Inc. (NASDAQ:OVID) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 663,000 shares, a drop of 39.2% from the October 31st total of 1,090,000 shares. Based on an average trading volume of 242,700 shares, the days-to-cover ratio is []
   Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $9.13  2021/11/24 14:34:41 Dakota Financial News
Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) have been given a consensus rating of Hold by the nine research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts []
   Ovid Therapeutics (NASDAQ:OVID) Lifted to Buy at Zacks Investment Research  2021/11/21 10:38:41 Dakota Financial News
Zacks Investment Research upgraded shares of Ovid Therapeutics (NASDAQ:OVID) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. The firm currently has $4.00 target price on the stock. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with []
   Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions  2021/04/19 13:16:52 Benzinga
Ovid Therapeutics Inc (NASDAQ: OVID ) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant safety signals observed, the company believes that efficacy outcomes observed in these trials do not support its further development. Now, the company … Full story available on Benzinga.com
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast

calendar